FLASCO

FLASCO News

BT5K 2019

BT5K 2019: Tampa Bay

BT5K Tampa Bay is part of the American Brain Tumor Association’s (ABTA) Breakthrough for Brain Tumors 5K series. Currently, more than 700,000 people in the U.S. are living with a brain tumor diagnosis. Your support allows the ABTA to fund desperately needed brain tumor research, patient programs, and support services. Join with your local brain...

taiho oncology

LONSURF® (trifluridine and tipiracil) tablets, for a new FDA-approved indication

On February 23, 2019, the U.S. Food and Drug Administration approved LONSURF® (trifluridine and tipiracil) tablets for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated  with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. 1LONSURF is also indicated for...

Florida Cancer Specialists Celebrates 35th Anniversary

Nation’s Largest Independent Hematology/Oncology Practice Reflects On More Than Three Decades of Advances in Cancer Care Fort Myers, FL – February 25, 2019. . . In February of 1984, Dr. William Harwin, Founder and President Emeritus of Florida Cancer Specialists & Research Institute (FCS), could only dream of what his fledgling community oncology/hematology practice might become...

The clonoSEQ® Assay is now FDA-cleared and covered by Medicare for detecting and monitoring MRD in bone marrow samples from patients with multiple myeloma or B-cell ALL.

View our Medicare coverage press release here. For more info about clonoSEQ, including test limitations, read the Technical Summary here. ABOUT ADAPTIVE BIOTECHNOLOGIES   As a pioneer and leader in the field of immunosequencing, Adaptive Biotechnologies combines next generation sequencing (NGS) and proprietary bioinformatics to profile T-cell and B-cell receptors to drive groundbreaking research in cancer and other...

FDA Approves Exelixis’ Cabozantinib for Advanced HCC

The FDA has approved cabozantinib (Cabometyx) as a treatment for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar), according to the company developing the therapy, Exelixis. The approval was based on findings from the phase III CELESTIAL trial, in which overall survival (OS) was improved by 2.2 months with cabozantinib versus placebo. Median...

Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Press Release See All Press Releases      Sign up for Email Alerts      Press Release RSS Sprycel is the first and only second-generation tyrosine kinase inhibitor for pediatric patients for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy Approval marks second pediatric leukemia indication for Sprycel 1 CATEGORY:  CORPORATE/FINANCIAL NEWSWEDNESDAY, JANUARY 2, 2019 4:25 PM EST#FDA...

Who’s Online

There are no users currently online